Veröffentlichungen
Originalarbeiten, Bücher, Buchkapitel und Übersichtsartikel von Prof. Marcus Maurer
Verwendung: Beginnen Sie mit einer Übersicht über alle Publikationen. Verwenden Sie Tag-Links, um markierte Dokumente aufzulisten oder eine ganze Kategorie aufzulisten, z.B. Original Work (Originalarbeiten), Books (Bücher), Book Chapters (Buchkapitel), Reviews (Übersichtsartikel). Wenn Sie wissen, was Sie suchen, dann geben Sie diesen Begriff in das Suchfeld ein.
New treatments for chronic urticaria
| Filename | 154. Kolkhir et al., New treatments chronic urt., AAAI 2020.pdf |
| Filesize | 1,65 MB |
| Version | r.154 |
| Date added | Juni 17, 2020 |
| Downloaded | 2 times |
| Category | Reviews |
| Authors | Kolkhir, P., Altrichter, S., Muñoz, M., Hawro, T., and Maurer, M. |
| Citation | Kolkhir, P., Altrichter, S., Muñoz, M., Hawro, T., and Maurer, M.: New treatments for chronic urticaria. Ann. Allergy Asthma Immunol. 2020: 124; 2-12. |
| Corresponding authors | Maurer, M. |
| DocNum | r.154 |
| DocType | |
| Edition; Page | 124; 2-12 |
| IF | 6.35 |
| Publisher | Ann. Allergy Asthma Immunol. |
| ReleaseDate | 2020 |
Objective: Chronic urticaria (CU) is a common, heterogeneous, and debilitating disease. Antihistamines and omalizumab are the mainstay therapies of CU. Additional treatment options are needed. Here, we review the off and beyond label use of licensed drugs, novel treatments that are currently under development, and promising new targets.
Data Sources: MEDLINE was searched for recent reports of the successful use of treatments in CU and promising targets for the development of novel treatment options. We also searched ClinicalTrials.gov for recent and ongoing randomized clinical trials in CU.
Study Selections: Relevant articles were selected and reviewed.
Results: Omalizumab, the treatment of choice in patients with antihistamine-resistant chronic spontaneous urticaria (CSU), should be explored for use in chronic inducible urticaria in children younger than 12 years with CSU and at higher doses. The off-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in CU. Ligelizumab and UB-221, 2 novel anti-IgE monoclonal antibodies, are in clinical trials for CU. Other promising drugs that are currently under development for CU are a chemoattractant receptor
(Last update: 12.2023)
| Number of original publications in peer-reviewed journals: | 580 |
| Number of reviews in peer-reviewed journals: | 210 |
| Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
| Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
| Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
| Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
Um die angebotenen Veröffentlichungen herunterladen zu können, müssen Sie sich einloggen. Wenn Sie das Login nicht kennen, schreiben Sie mir bitte Ihre Anfrage.